Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients [Estudio abierto para determinar la seguridad a largo plazo de la Safinamida en pacientes con enfermedad de Parkinson].

Trial Profile

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients [Estudio abierto para determinar la seguridad a largo plazo de la Safinamida en pacientes con enfermedad de Parkinson].

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Safinamide (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Newron Sweden AB
  • Most Recent Events

    • 11 Aug 2012 Company (Newron Pharmaceuticals) added as reported by European Clinical Trials Database record.
    • 30 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov record.
    • 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top